Blake Embrey
Nurse Practitioner · Coldwater, MSNPI 1770007452
Payments from drug & device makers
Across 306 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$822
- GSK$605
- AstraZeneca$525
- Novo Nordisk$481
- Boehringer Ingelheim$344
- Corcept Therapeutics$244
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,025100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $822 |
| GSK | 44 | $605 |
| AstraZeneca | 31 | $525 |
| Novo Nordisk | 24 | $481 |
| Boehringer Ingelheim | 19 | $344 |
| Corcept Therapeutics | 13 | $244 |
| Dexcom, Inc. | 15 | $216 |
| Lilly USA, LLC | 18 | $199 |
| Amarin Pharma, Inc. | 10 | $144 |
| Bayer | 8 | $137 |
| Novartis | 8 | $128 |
| Johnson & Johnson | 8 | $127 |
| Genentech USA, Inc. | 1 | $125 |
| Sunovion Pharmaceuticals Inc. | 6 | $110 |
| Teva Pharmaceuticals USA, Inc. | 4 | $96 |
| Esperion Therapeutics, Inc. | 5 | $86 |
| Pfizer | 5 | $73 |
| Pacira Therapeutics, Inc. | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $66 |
| Ultragenyx Pharmaceutical Inc. | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $60 |
| Biohaven Pharmaceuticals, Inc. | 3 | $38 |
| Ironwood Pharmaceuticals, Inc | 2 | $33 |
| Paratek Pharmaceuticals, Inc. | 2 | $32 |
| Nevro Corp. | 1 | $31 |
| Kowa Pharmaceuticals America, Inc. | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Merck | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| Inogen, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,025 in reported general payments places this provider in the 90th percentile of 1,090 nurse practitioner providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 195 | $140,061 |
| OzempicSemaglutide | 85 | $86,087 |
| RybelsusSemaglutide | 51 | $76,017 |
| JardianceEmpagliflozin | 52 | $54,976 |
| EntrestoSacubitril/Valsartan | 59 | $51,773 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $39,697 |
| LinzessLinaclotide | 59 | $38,135 |
| TrulicityDulaglutide | 26 | $33,450 |
| XareltoRivaroxaban | 35 | $32,385 |
| EliquisApixaban | 41 | $23,403 |
| MounjaroTirzepatide | 16 | $16,668 |
| TradjentaLinagliptin | 30 | $16,366 |
| GemtesaVibegron | 18 | $12,543 |
| TrintellixVortioxetine Hydrobromide | 20 | $11,644 |
| VascepaIcosapent Ethyl | 19 | $9,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $481 | $162,105136 claims |
| AstraZenecaFarxiga, Brilinta | $525 | $145,976206 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Spiriva Respimat | $344 | $89,021115 claims |
| NovartisEntresto | $128 | $51,77359 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $199 | $50,11842 claims |
| GSKTrelegy Ellipta | $605 | $39,69750 claims |
| AbbVieLinzess | $822 | $38,13559 claims |
| Johnson & JohnsonXarelto | $127 | $32,38535 claims |
| PfizerEliquis | $73 | $23,40341 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $66 | $11,64420 claims |
| MerckJanuvia | $17 | $7,15511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,090 nurse practitioner providers in Mississippi.
Other nurse practitioner in Coldwater
- Christina TreppendahlRidgeland$673K
- Catherine WellsJackson$75K
- Jo Anna WarrenJackson$73K
- Marisa StringerBiloxi$68K
- Sara KlausFlowood$48K
- Micaela PerkinsOxford$32K
- Michelle TharpJackson$28K
- Kaylon LewisHattiesburg$25K
- Jennifer HollyJackson$16K
- Mariah CoxGulfport$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.